Authors
Latest:
In Response: Why the Passing of H.R.2541 Is NeededRon Lattanze, MBA, provided his commentary regarding why H.R.2541 or the Nuclear Medicine Clarification Act of 2025 should be passed.
Latest:
CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple MyelomaPanelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
Latest:
Face-Off: Award CeremonyFollowing a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Latest:
Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBCNew findings reveal that adding durvalumab to neoadjuvant chemotherapy does not enhance HRQOL in muscle-invasive bladder cancer patients.
Latest:
Empowering Awareness to Address Rising Gynecological Cancer IncidenceGinger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Latest:
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell TumorIn this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
Latest:
Elevating the Quality of Cancer Care via Cross-Department CollaborationExperts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
Latest:
Addressing Common Talquetamab MisunderstandingsPanelists discuss how health care providers and patients should understand that talquetamab's unique adverse effects are temporary and resolve over time, even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.
Latest:
Highlighting Ongoing Clinical Trials in CML From ASHKendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Latest:
Improving the Management of HNSCC: Next StepsDr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.
Latest:
Unusual Clinical Presentation of Clear Cell Sarcoma in a Young WomanA young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM TreatmentThe panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Latest:
Unveiling Advances in GU Cancers: Insights from Oncology DecodedDive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Latest:
Key Takeaways: Optimal Use of JAK Inhibitors in MF and Future Directions in CarePanelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.
